Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab

Bookmark and Share
Published: 17 Jun 2020
Views: 380
Rating:
Save
Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, USA

Prof Randy Hecht talks to ecancer in an online interview about talimogene laherparepvec (T-VEC) and it's use in a recent trial presented at the ASCO 2020 virtual meeting.

Prof Hecht gives a thorough background on the use of T-VEC and it's use in oncology.

He then outlines the phase 1b, multi-centre, open-label, dose escalation study (NCT02509507) which evaluates the safety of intrahepatic injection of T-VEC in combination with intravenous pembrolizumab in patients with hepatocellular carcinoma or liver metastases.

Prof Hecht provides some throughs of the future potential of T-VEC and the next developments for this trial.